#49761
Re: Chicharros USA - bolsa internacional
BCRX
He hecho un repasillo de la transcripción de la cc del miércoles, y os paso algunos apuntes, que considero interesantes...
BEROTRALSTAT.
"We are in an extraordinary position at BioCryst. The company is said to receive 3 approvals within the next 12 months for berotralstat.
We expect our first global approval in Japan in the second half of the year. We have a December 3 PDUFA date from the FDA. And in Europe, our MAA was validated in March and we expect approval about that time next year."
"And we announced yesterday that we have a new composition of matter patent that will extend our patent protection by 4 years to 2039. Add to that market potential for 9930 in an established market of more than $4 billion for treatment of complement-mediated diseases, and we see a significant opportunity for even greater value creation."
GALIDESIVIR.
"Patient dosing has begun in our clinical trial in Brazil and we look forward to generating data to determine if galidesivir could help in this global health emergency."
CASH.
"With $115 million we reported at the end of Q1, we have sufficient capital to get us through this year and into the early part of next year"
"We have several additional potential capital sources to provide financial flexibility as we progress through the year. We expect to trigger up to $20 million milestone with – from Torii. Also our data from BCX9930 provides options to add capital such as a partnership to advance that program. And additionally, we’re evaluating royalty and/or debt financing for berotralstat that would bring in capital at approval to fund the launch."
NEXT EVENTS.
May 14, 2020 at 9:00 AM EDT | Bank of America 2020 Healthcare Conference
May 20, 2020 at 3:40 PM EDT | 2020 RBC Capital Markets Global Healthcare Conference
In con 2,5k títulos a 3,98
He hecho un repasillo de la transcripción de la cc del miércoles, y os paso algunos apuntes, que considero interesantes...
BEROTRALSTAT.
"We are in an extraordinary position at BioCryst. The company is said to receive 3 approvals within the next 12 months for berotralstat.
We expect our first global approval in Japan in the second half of the year. We have a December 3 PDUFA date from the FDA. And in Europe, our MAA was validated in March and we expect approval about that time next year."
"And we announced yesterday that we have a new composition of matter patent that will extend our patent protection by 4 years to 2039. Add to that market potential for 9930 in an established market of more than $4 billion for treatment of complement-mediated diseases, and we see a significant opportunity for even greater value creation."
GALIDESIVIR.
"Patient dosing has begun in our clinical trial in Brazil and we look forward to generating data to determine if galidesivir could help in this global health emergency."
CASH.
"With $115 million we reported at the end of Q1, we have sufficient capital to get us through this year and into the early part of next year"
"We have several additional potential capital sources to provide financial flexibility as we progress through the year. We expect to trigger up to $20 million milestone with – from Torii. Also our data from BCX9930 provides options to add capital such as a partnership to advance that program. And additionally, we’re evaluating royalty and/or debt financing for berotralstat that would bring in capital at approval to fund the launch."
NEXT EVENTS.
May 14, 2020 at 9:00 AM EDT | Bank of America 2020 Healthcare Conference
May 20, 2020 at 3:40 PM EDT | 2020 RBC Capital Markets Global Healthcare Conference
In con 2,5k títulos a 3,98